B&H MED Secures Strategic Investment to Launch GMP Smart Factory for Injection Pens with Annual Capacity Exceeding 100 Million Units

Baojuhe (Suzhou) Medical Technology Co., Ltd. (hereinafter referred to as “Baojuhe Medical”) officially announced the completion of strategic financing.

This round of financing was led byLed by Dandelion Venture Capital and Xindanuocheng Venture Capital, with participation from institutions such as Xinqi Industrial Investment and Dandelion Jiangnan Venture Capital, as well as industrial investors including Zhejiang JiangnanCo-investment. This financing round will accelerate the construction of Baojuhe Medical’s GMP-compliant smart factory for injection pens, achieving an annual production capacity exceeding 100 million units, and further solidifying Baojuhe Medical’s leading position in the global market for self-administration devices.

Baojuhe Medical (B&H MED) specializes in process research for self-administration devices within the broader healthcare sector, providing comprehensive solutions and serving global customers through technological innovation. The company has assembled top-tier talent from the self-administration device industry, enabling it to offer not only product research and development for self-administration devices but also integrated systems of instruments and devices related to self-administration throughout the entire drug development-to-clinical trial process. Baojuhe has successfully developed the LoonGBIOPen.^®、Beinghigher^®LoonGBIOPen, along with a range of disposable injection pens, has undergone R&D validation and compatibility testing with multiple pharmaceutical manufacturers.^®Baojuhe has secured tens of millions of units in indicative orders for its injection pen._®All injection pen products are independently developed and protected by proprietary invention patents. The products are compatible with all pre-filled syringe-based injectable medications, offering a wide range of application scenarios. In the second half of 2024, Baojuhe completed the drug packaging material filing and registration for its first injection pen with the National Medical Products Administration (NMPA). By the end of April this year, the NMPA filing and registration for three additional pen models will be completed. Adhering to the development philosophy of "Pursuing Excellence, Delivering Value, and Achieving Win-Win Cooperation," B&H MED will establish sales and technical service centers in multiple cities across China and in overseas regions, committing to providing dedicated service to global customers.

Amid the continued heating up of the global GLP-1 drug market, global sales of GLP-1 products, represented by semaglutide and tirzepatide, surpassed the $50 billion mark in 2024. This growth trend is particularly significant in the Chinese market—according to forecasts by Founder Securities, the market size for GLP-1 weight-loss drugs in China is expected to exceed RMB 37.8 billion by 2030. Notably, the domestic injection pen market remains dominated by foreign brands, and high product prices have limited drug accessibility to some extent. As GLP-1 drugs are projected to experience explosive growth in 2026, Chinese manufacturers of injection pens are seizing unprecedented development opportunities. The 2025 "Two Sessions" prominently highlighted the issue of "weight management," with the Director of the National Health Commission explicitly stating that medical institutions would be encouraged to establish weight management clinics to systematically provide weight management services. These measures signal that China's weight-loss market will enter a new phase of standardized and large-scale development, creating broad growth space for the entire industry chain. Benefiting from the dual advantages of expanding market demand and increased policy support, Chinese injection pen manufacturers with technological accumulation and cost advantages are poised to achieve breakthrough development in this blue-ocean market. In the future, as the pace of domestic substitution accelerates, Made-in-China products will contribute significantly to improving the nation's health management standards.

Leveraging its unique asset-light operational model and the technical expertise of its seasoned industry team, Baojuhe Medical has successfully established industrial barriers with core competitiveness. The company not only possesses the capability for rapid, customized service responses but also provides comprehensive quality assurance through a well-equipped laboratory infrastructure. Currently, the injection pen products manufactured by Baojuhe Medical fully meet the precision requirements of the ISO 11608 international standard. This achievement serves as strong testament to its technological prowess and lays a solid foundation for expanding into international markets. By continuously optimizing cost structures and enhancing service efficiency, the company is accelerating its global market network deployment, committed to delivering high-quality, cost-effective products to customers both domestically and abroad. With recognition from the capital market, Baojuhe Medical will continue to strengthen its technological innovation advantages, contributing to the advancement of global health through more precise and reliable self-administration solutions.

Qin Ping, Founder of Baojuhe MedicalStatement: We extend our sincere gratitude to Dandelion (Shenzhen) Pharmaceutical Venture Capital Co., Ltd., Cinda Nuocheng Venture Capital, Xinqi Industrial Investment, Zhejiang Jiangnan, and other investment institutions and enterprises for their strong support. This round of strategic investment will inject powerful momentum into the future rapid development of Baojuhe Medical. Recently, we have secured letters of intent for orders totaling tens of millions of injection pens, and our team is accelerating all related work processes. Following this round of financing, Baojuhe Medical will officially commence the design and construction of a planned smart factory for injection pens. By the end of June this year, we will complete the commissioning of the second automated production line for injection pens. By the end of 2025, we will complete the construction and launch of three additional digital production lines for injection pens. In March 2026, Baojuhe will complete the full construction and commence operations of its GMP-compliant smart factory for injection pens, achieving fully automated and intelligent production. The planned production capacity will exceed 100 million units, with products covering disposable injection pens, electronic injection pens, and KanGFSX.^®and other product series. The operation of Baojuhe’s GMP-compliant smart factory will significantly enhance the consistency of Baojuhe’s injection pen products, ensuring product quality and timely order fulfillment for global customers.

Zhang Jinwei, Founder of Dandelion and Lifetime Fellow of the Royal Society of ArtsIt was stated that as China’s aging population issue intensifies and the number of patients with chronic diseases grows, opportunities are emerging for the self-administration device industry. Self-administration devices featuring broad applicability, high safety and reliability, precise injection accuracy, and good portability will garner increasing attention and recognition. Driven by application demands, China’s self-administration device industry still has significant room for expansion. It is hoped that Baojuhe (Suzhou) Medical Technology Co., Ltd. will benchmark against leading global enterprises, continuously pursue technological innovation, ensure product quality, and become a leader in the self-administration device industry.

Xiang Chao, Founder of Xindanuocheng and Director of the Shenzhen Biomedical Industry AllianceThis signifies that by leveraging GLP-1 as an entry point and educating and expanding the market through its配套 injection pens, the market potential for self-administered injections and accompanying devices has been unlocked. Meanwhile, with the support of our industrial strategic partner, Dandelion (Shenzhen) Pharmaceutical Venture Capital Co., Ltd., and the backing of our capital strategic partner, Qianhai Xinnuo, I am confident that the company will seize the initiative to lead, sustain its competitive edge, and rapidly harness the synergy between the primary and secondary capital markets, thereby gaining the momentum for soaring growth!